title: Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib.
abstract: Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib. We report a unique case of diffuse cutaneous hypopigmentation induced by dasatinib followed by hyperpigmentation occurring in the same patient. A 52-year-old African American female with a history of metastatic hemangiopericytoma was initiated on dasatinib as part of a clinical trial. After 2 months of treatment, she developed generalized skin hypopigmentation. Within 1 month of discontinuing the drug, the patient's skin pigmentation returned to normal. However, she then developed diffuse skin hyperpigmentation over the next couple of months. The hyperpigmentation was self-limited, and eventually resolved after several months.
authors.affiliation: Clinical Lecturer, Division of General Medicine, Department of Internal Medicine, University of Michigan Health System , Ann Arbor, MI, USA .
authors.forename: Karim
authors.initials: K
authors.lastname: Boudadi
authors.affiliation: Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System , Ann Arbor, MI, USA .
authors.forename: Rashmi
authors.initials: R
authors.lastname: Chugh
keywords: Sarcoma; Skin pigmentation; Tyrosine kinase inhibitor (TKI)